Novartis AG ADR

Novartis develops and sells prescription medicines across cardiovascular disease (Entresto for heart failure), immunology (Cosentyx for psoriasis and arthritis), oncology (Pluvicto for prostate cancer, Kisqali for breast cancer), and rare diseases (Zolgensma for spinal muscular atrophy) [Yahoo Finance]. The company operates globally, manufacturing drugs in multiple countries and selling through hospitals, clinics, and specialty pharmacies [Yahoo Finance].

Novartis is a Swiss pharmaceutical giant with over 75,000 employees making drugs for heart disease, cancer, immune disorders, and rare genetic conditions [Yahoo Finance]. The company posted $54.8B in revenue with strong margins (75% gross, 32% operating) and solid cash generation ($17.7B free cash flow), reflecting a diversified portfolio of branded medicines [Yahoo Finance]. Recent positive clinical trial results for Pluvicto, a radioactive cancer therapy, have driven modest stock gains and positioned Novartis as a leader in an emerging treatment category [Simply Wall St].

Novartis is financially healthy with strong profitability, low leverage, and consistent cash generation [Yahoo Finance].